Derbyshire Medicines Management and Clinical Policies
A number of high cost drugs, devices, procedures and products have been excluded from the scope of the national tariff of payment by results . Following the re-organisation of the NHS these drugs are commissioned by:
A detailed list of the NHS National Tariff Payment System for 2022 to 2023 is available here
A summary of PbR excluded from tariff drugs commissioned by ICB or NHSE is available here (2022-23)
A detailed list of medicines directly commissioned by NHS England is available here - (Version 17. 2022-23)
NHS England are the responsible commissioners for the management of the Cancer Drugs Fund. For details of the CDF click here
A list of technologies with approved Patient Access Schemes is available here
The Manual - this is a technical document describing the prescribed specialised services, some of these are directly commissioned by NHS England and some by ICBs
Commissioning intentions - this serves as notice to all providers of specialised services in England of changes and priorities for the coming year
Gain Sharing - principles for sharing the benefits associated with more efficient use of medicines not reimbursed through national tariff prices
A significant proportion of high cost drugs excluded from tariff are commissioned by Derbyshire in line with NICE Technology Appraisals.
Biologic algorithms for use in Dermatology, Gastroenterology, Ophthalmology, Rheumatology, Cardiology and Neurology are listed below:
| Speciality |
Last updated |
| Cardiology | |
| Primary hypercholesterolaemia and mixed dyslipidaemia | October 2019 |
| Dermatology | |
| Atopic Dermatitis |
September 2022 |
| Psoriasis |
November 2021 |
| Gastroenterology |
|
| Crohn's Disease |
August 2020 |
| Ulcerative Colitis |
January 2023 |
| Neurology | |
| Migraine | March 2022 |
| Sodium oxybate | November 2019 |
| Ophthalmology | |
| Age-Related Macular Degeneration (ARMD) | July 2022 |
| Diabetic Macular Oedema (DMO) | September 2022 |
| Macular Oedema due to BRVO/CRVO | January 2020 |
| Non-Infectious Posterior Uveitis | September 2019 |
| Osteoporosis | |
| Romosozumab | July 2022 |
| Rheumatology | |
| Ankylosing Spondylitis | March 2023 |
| Psoriatic Arthritis | September 2022 |
| Moderate Rheumatoid Arthritis | August 2021 |
| Severe Rheumatoid Arthritis | April 2021 |
